��������

Scott Hutton is the current CEO at Biodesix. Prior to this, they were the Senior Vice President & General Manager, CEO-in-waiting at Spectranetics from January 2017 to December 2017. Scott was responsible for leadership of the $181.6M Vascular Intervention (VI) business and teams consisting of 750+ teammates with an expense budget of $84.2M.

Under their leadership, the company achieved >10% quarterly growth (11% (Q1), and 11% (Q2)) over prior year, generated $46.4M (Q1), $51.0M (Q2), and achieved 24% Net Promoter Score (NPS) for FY17 vs. 18% prior year (FY16). Additionally, the company was awarded ColoradoBiz Magazine “Top Company” in Manufacturing (2017), and BrainShark Sharkie Sales Enablement Program of the Year (2017).

Hutton participated in the sale of Spectranetics Corp to Royal Philips Image Guided Therapy (IGT) Business Group for $2.2B. Scott then led post-acquisition integration on the Spectranetics Vascular Interventions (VI) side. Scott also launched two products (Stellarex Drug-Coated 0.035” OTW Angioplasty Balloon (DCB) in July, Turbo-Power 6Fr Laser Atherectomy Catheter in February).

Scott Hutton completed their undergraduate degree at Purdue University in the College of Health and Human Sciences, majoring in Health & Kinesiology.

Ryan Siurek - Chief Accounting Officer, Leona Hamrick - VP, Clinical Development & Medical Affairs, and Steve Springmeyer - Co-Chief Medical Officer report to Scott Hutton.